Prognostic value of the detection of lymph node micrometastases in colon cancer.
OBJECTIVE
A study is made of the clinical repercussions of occult metastases-micrometastases (MMs+)-or isolated tumour cells (ITCs+) in the lymph nodes of patients with stage IIA and IIB colon adenocarcinoma initially considered as corresponding to N0.


METHODS
A retrospective study of 39 patients with stage IIA and IIB (T3-T4 N0 M0) colon adenocarcinoma, subjected to similar surgical and adjuvant chemotherapy treatment, with long and careful follow-up (minimum: 5 years, mean: 81.7 months) was performed on their previously resected lymph nodes, with the aid of new histological and immunohistochemical (cytokeratin) sections, in order to detect MMs or ITCs. Disease-free survival (DFS) and global survival (GS) in the two groups (patients with MMs+ or ITCs+ vs. patients without MMs or ITCs) were compared at 5 years based on the corresponding Kaplan-Meier survival curves, with the Breslow test.


RESULTS
A total of 382 lymph nodes from the 39 patients (mean: 9.8; standard deviation: 6.09) were revised. MMs+ were detected in 2 cases and ITCs+ in 2 more cases on the Cytokeratin study. GS of the whole series at 5 years was 89.74% (35 patients alive) with a DFS at 5 years of 79.49% (31 patients free of disease), but the 2 cases with MMs+ were dead at 5 years, with high statistical differences between both groups (MMs+/MMs-) (p<0.0001). When comparing the group of MMs+/ITCs+ patients and the group of MM-/ITCs- patients, the DFS and GS times at 5 years were higher in the MMs-/ITCs- group (p=0.0692 and p=0.006 respectively).


CONCLUSIONS
Although the incidence of MMs+ or ITCs+ in the examined lymph nodes was low, the presence of MMs is related to a dramatic reduction in GS and DFS at 5 years. We encourage a detailed histological study of lymph nodes resected in patients with deep penetrating colon tumours in order to assure a pN0 status.
Bosch Roig
Carlos E
CE
Medical Oncology Unit, Dr. Peset University Hospital, Valencia, Spain. bosch_car@gva.es
Roselló-Sastre
Ester
E
Alonso Hernández
Sonia
S
Almenar Cubells
Daniel
D
Grau Cardona
Enrique
E
Camarasa Lillo
Natalia
N
Bautista
Daniel
D
Molins Palau
Carmen
C
D000230:Adenocarcinoma / Q000556:secondary* / Q000601:surgery; D002288:Adenocarcinoma, Mucinous / Q000556:secondary* / Q000601:surgery; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D003110:Colonic Neoplasms / Q000097:blood* / Q000473:pathology* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007633:Keratins / Q000378:metabolism; D008198:Lymph Nodes / Q000473:pathology* / Q000601:surgery; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate
D007633:Keratins
Eur J Surg. 1996 Aug;162(8):637-42
8891622
J Clin Oncol. 1999 Sep;17(9):2896-900
10561368
Ann Surg Oncol. 2003 Jan-Feb;10(1):65-71
12513963
J Clin Oncol. 2003 Aug 1;21(15):2912-9
12885809
Cancer. 2003 Dec 15;98(12):2740-1
14669301
Mod Pathol. 2004 Apr;17(4):402-6
14976530
Ann Intern Med. 1995 Mar 1;122(5):321-6
7847642
Arch Surg. 1989 Feb;124(2):180-2
2916939
Dis Colon Rectum. 1997 Dec;40(12):1465-71
9407986
J Clin Oncol. 2002 Oct 15;20(20):4232-41
12377967
J Surg Oncol. 2004 Mar;85(3):166-70
14991889
Cancer. 1994 Feb 1;73(3):563-9
7507795
CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308
15537574
J Pathol. 1994 Feb;172(2):183-7
7513353
JAMA. 1990 Sep 19;264(11):1444-50
2202842
Dis Colon Rectum. 1991 Oct;34(10):917-20
1717210
J Natl Cancer Inst. 2005 Feb 2;97(3):219-25
15687365
Clin Transl Oncol. 2006 Sep;8(9):676-80
17005470
Int J Colorectal Dis. 1998;13(2):99-102
9638496
Colorectal Dis. 2003 Mar;5(2):164-8
12780907
J Clin Oncol. 2004 Aug 15;22(16):3408-19
15199089
Dis Colon Rectum. 1998 Oct;41(10):1244-9
9788387
Ann Surg Oncol. 2001 May;8(4):300-4
11352302
N Engl J Med. 1998 Jul 23;339(4):223-8
9673300